Elite Pharmaceuticals, Inc. — Operating Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/ee712d66-634d-4d3c-a641-7649fabe27b1/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $49.1M | 2025-04-01 – 2026-03-31 | evidence 0001493152-26-031070 |
| FY 2024 | $19.6M | 2024-04-01 – 2025-03-31 | evidence 0001641172-25-017134 |
| FY 2023 | $10.8M | 2023-04-01 – 2024-03-31 | evidence 0001493152-24-025829 |
| FY 2022 | $3.7M | 2022-04-01 – 2023-03-31 | evidence 0001493152-23-022936 |
| FY 2021 | $5.1M | 2021-04-01 – 2022-03-31 | evidence 0001493152-22-018108 |
| FY 2020 | $2.1M | 2020-04-01 – 2021-03-31 | evidence 0001213900-21-032329 |
| FY 2019 | $-2.3M | 2019-04-01 – 2020-03-31 | evidence 0001213900-20-016181 |
| FY 2018 | $-9.2M | 2018-04-01 – 2019-03-31 | evidence 0001213900-19-011224 |
| FY 2017 | $-9.1M | 2017-04-01 – 2018-03-31 | evidence 0001144204-18-034237 |
| FY 2016 | $-7.4M | 2016-04-01 – 2017-03-31 | evidence 0001144204-17-032547 |
| FY 2015 | $-8.3M | 2015-04-01 – 2016-03-31 | evidence 0001144204-16-108327 |
| FY 2014 | $-16.5M | 2014-04-01 – 2015-03-31 | evidence 0001144204-16-108327 |
| FY 2013 | $-5.3M | 2013-04-01 – 2014-03-31 | evidence 0001144204-14-040327 |
| FY 2012 | $-1.6M | 2012-04-01 – 2013-03-31 | evidence 0001144204-13-036025 |
| FY 2011 | $-2.0M | 2011-04-01 – 2012-03-31 | evidence 0001144204-12-037392 |
| FY 2010 | $-885.8k | 2010-04-01 – 2011-03-31 | evidence 0001144204-12-037392 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Elite Pharmaceuticals, Inc. — all facts · Revenue · Net Income